U.S. flag

An official website of the United States government

NM_000535.7(PMS2):c.1144+3A>T AND Hereditary cancer-predisposing syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Aug 17, 2017
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000573850.3

Allele description [Variation Report for NM_000535.7(PMS2):c.1144+3A>T]

NM_000535.7(PMS2):c.1144+3A>T

Gene:
PMS2:PMS1 homolog 2, mismatch repair system component [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
7p22.1
Genomic location:
Preferred name:
NM_000535.7(PMS2):c.1144+3A>T
HGVS:
  • NC_000007.14:g.5989797T>A
  • NG_008466.1:g.24310A>T
  • NM_000535.7:c.1144+3A>TMANE SELECT
  • NM_001322003.2:c.739+3A>T
  • NM_001322004.2:c.739+3A>T
  • NM_001322005.2:c.739+3A>T
  • NM_001322006.2:c.988+2176A>T
  • NM_001322007.2:c.826+3A>T
  • NM_001322008.2:c.826+3A>T
  • NM_001322009.2:c.739+3A>T
  • NM_001322010.2:c.583+2176A>T
  • NM_001322011.2:c.211+3A>T
  • NM_001322012.2:c.211+3A>T
  • NM_001322013.2:c.571+3A>T
  • NM_001322014.2:c.1144+3A>T
  • NM_001322015.2:c.835+3A>T
  • LRG_161t1:c.1144+3A>T
  • LRG_161:g.24310A>T
  • NC_000007.13:g.6029428T>A
  • NM_000535.5:c.1144+3A>T
Links:
dbSNP: rs1430015665
NCBI 1000 Genomes Browser:
rs1430015665
Molecular consequence:
  • NM_000535.7:c.1144+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322003.2:c.739+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322004.2:c.739+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322005.2:c.739+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322006.2:c.988+2176A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322007.2:c.826+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322008.2:c.826+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322009.2:c.739+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322010.2:c.583+2176A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322011.2:c.211+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322012.2:c.211+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322013.2:c.571+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322014.2:c.1144+3A>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001322015.2:c.835+3A>T - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV000663565Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)		Uncertain significance
(Aug 17, 2017) 		germlineclinical testing

Citation Link

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Ambry Genetics, SCV000663565.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The c.1144+3A>T intronic variant results from an A to T substitution 3 nucleotides after coding exon 10 in the PMS2 gene. This nucleotide position is well conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to weaken the efficiency of the native splice donor site; however, direct evidence is unavailable. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024